Cargando…

Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation

BACKGROUND: Pulmonary autograft reinforcement to prevent dilatation and subsequent neo-aortic valve regurgitation has been reported; however, data on long-term function of the neo-aortic valve after this modified Ross procedure are lacking. Our objective here was to assess long-term outcomes of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Guirgis, Lisa, Hascoet, Sébastien, Van Aerschot, Isabelle, Radojevic, Jelena, Ly, Mohamed, Cohen, Sarah, Belli, Emre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938391/
https://www.ncbi.nlm.nih.gov/pubmed/36820346
http://dx.doi.org/10.1016/j.xjtc.2022.11.016
_version_ 1784890618822000640
author Guirgis, Lisa
Hascoet, Sébastien
Van Aerschot, Isabelle
Radojevic, Jelena
Ly, Mohamed
Cohen, Sarah
Belli, Emre
author_facet Guirgis, Lisa
Hascoet, Sébastien
Van Aerschot, Isabelle
Radojevic, Jelena
Ly, Mohamed
Cohen, Sarah
Belli, Emre
author_sort Guirgis, Lisa
collection PubMed
description BACKGROUND: Pulmonary autograft reinforcement to prevent dilatation and subsequent neo-aortic valve regurgitation has been reported; however, data on long-term function of the neo-aortic valve after this modified Ross procedure are lacking. Our objective here was to assess long-term outcomes of the modified Ross procedure with autograft reinforcement using the reimplantation technique. PATIENTS: The outcomes of 61 consecutive patients managed using the Dacron-conduit reinforced Ross procedure between 2009 and 2021 were reviewed. Most patients had a unicuspid or bicuspid aortic valve (n = 52; 85%), predominant aortic valve regurgitation (n = 42; 77%), and >30 mm dilatation of the ascending aorta (n = 33; 54%). A prior aortic valve procedure was noted in 47 patients (77%) patients, including 38 (62%) with surgical repair and 9 (15%) with balloon dilatation. The pulmonary autograft was reimplanted within a Dacron conduit with a median diameter of 25.6 mm (range, 20-30 mm) using the David valve-sparing aortic root replacement technique. RESULTS: All patients survived. The median age at surgery was 16.8 years (range, 6-38 years). Neo-aortic valve replacement was required in 3 patients (4.9%; 95% CI, 0.34%- 12.7%) because of infective endocarditis, left ventricular false aneurysm, and leaflet perforation, respectively; the repeat procedure was done early in 2 of these patients (2 of 61; 3%). Six patients required right ventricular outflow conduit replacement, 5 by surgery and 1 percutaneously. The median duration of follow-up was 90 months (range, 10-124 months). The 5- and 10-year rates of reintervention-free survival were 84.3% (95% CI, 74%-95%) and 81.6% (95% CI, 72%-93%), respectively, and 5-year survival without aortic reintervention was 94.5% (95% CI, 88%-100%), with little change at 10 years. No patients experienced deterioration of initial neo-aortic valve function (ie, regurgitation or stenosis). CONCLUSIONS: Autograft reinforcement using the reimplantation technique allowed expansion of Ross procedure indications to all patients requiring aortic valve replacement and prevented neo-aortic root dilatation. Failures were uncommon. Long-term follow-up data showed stable neo-aortic valve function.
format Online
Article
Text
id pubmed-9938391
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99383912023-02-19 Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation Guirgis, Lisa Hascoet, Sébastien Van Aerschot, Isabelle Radojevic, Jelena Ly, Mohamed Cohen, Sarah Belli, Emre JTCVS Tech Congenital: Aortic Valve BACKGROUND: Pulmonary autograft reinforcement to prevent dilatation and subsequent neo-aortic valve regurgitation has been reported; however, data on long-term function of the neo-aortic valve after this modified Ross procedure are lacking. Our objective here was to assess long-term outcomes of the modified Ross procedure with autograft reinforcement using the reimplantation technique. PATIENTS: The outcomes of 61 consecutive patients managed using the Dacron-conduit reinforced Ross procedure between 2009 and 2021 were reviewed. Most patients had a unicuspid or bicuspid aortic valve (n = 52; 85%), predominant aortic valve regurgitation (n = 42; 77%), and >30 mm dilatation of the ascending aorta (n = 33; 54%). A prior aortic valve procedure was noted in 47 patients (77%) patients, including 38 (62%) with surgical repair and 9 (15%) with balloon dilatation. The pulmonary autograft was reimplanted within a Dacron conduit with a median diameter of 25.6 mm (range, 20-30 mm) using the David valve-sparing aortic root replacement technique. RESULTS: All patients survived. The median age at surgery was 16.8 years (range, 6-38 years). Neo-aortic valve replacement was required in 3 patients (4.9%; 95% CI, 0.34%- 12.7%) because of infective endocarditis, left ventricular false aneurysm, and leaflet perforation, respectively; the repeat procedure was done early in 2 of these patients (2 of 61; 3%). Six patients required right ventricular outflow conduit replacement, 5 by surgery and 1 percutaneously. The median duration of follow-up was 90 months (range, 10-124 months). The 5- and 10-year rates of reintervention-free survival were 84.3% (95% CI, 74%-95%) and 81.6% (95% CI, 72%-93%), respectively, and 5-year survival without aortic reintervention was 94.5% (95% CI, 88%-100%), with little change at 10 years. No patients experienced deterioration of initial neo-aortic valve function (ie, regurgitation or stenosis). CONCLUSIONS: Autograft reinforcement using the reimplantation technique allowed expansion of Ross procedure indications to all patients requiring aortic valve replacement and prevented neo-aortic root dilatation. Failures were uncommon. Long-term follow-up data showed stable neo-aortic valve function. Elsevier 2022-12-20 /pmc/articles/PMC9938391/ /pubmed/36820346 http://dx.doi.org/10.1016/j.xjtc.2022.11.016 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Congenital: Aortic Valve
Guirgis, Lisa
Hascoet, Sébastien
Van Aerschot, Isabelle
Radojevic, Jelena
Ly, Mohamed
Cohen, Sarah
Belli, Emre
Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation
title Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation
title_full Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation
title_fullStr Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation
title_full_unstemmed Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation
title_short Outcomes after the Ross procedure with pulmonary autograft reinforcement by reimplantation
title_sort outcomes after the ross procedure with pulmonary autograft reinforcement by reimplantation
topic Congenital: Aortic Valve
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938391/
https://www.ncbi.nlm.nih.gov/pubmed/36820346
http://dx.doi.org/10.1016/j.xjtc.2022.11.016
work_keys_str_mv AT guirgislisa outcomesaftertherossprocedurewithpulmonaryautograftreinforcementbyreimplantation
AT hascoetsebastien outcomesaftertherossprocedurewithpulmonaryautograftreinforcementbyreimplantation
AT vanaerschotisabelle outcomesaftertherossprocedurewithpulmonaryautograftreinforcementbyreimplantation
AT radojevicjelena outcomesaftertherossprocedurewithpulmonaryautograftreinforcementbyreimplantation
AT lymohamed outcomesaftertherossprocedurewithpulmonaryautograftreinforcementbyreimplantation
AT cohensarah outcomesaftertherossprocedurewithpulmonaryautograftreinforcementbyreimplantation
AT belliemre outcomesaftertherossprocedurewithpulmonaryautograftreinforcementbyreimplantation